NIH PAR · NCI · R34

PAR-25-104: Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Open for applicationsNext due date: Oct 25, 2026Expires Oct 26, 2027

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely.…

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
PAR-25-104
Type
PAR
Activity code
R34
Primary institute
NCI · National Cancer Institute
Clinical trials
Optional
Posted
Nov 5, 2024
Opens
Jan 25, 2025
Expires
Oct 26, 2027

PAR-25-104 due dates

4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for PAR-25-104
Application Due Date(s)Renewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
February 25, 2025February 25, 2025Not ApplicableJuly 2025October 2025December 2025
June 25, 2025June 25, 2025Not ApplicableNovember 2025January 2026April 2026
October 25, 2025October 25, 2025Not ApplicableMarch 2026May 2026July 2026
February 25, 2026February 25, 2026Not ApplicableJuly 2026October 2026December 2026
June 25, 2026June 25, 2026Not ApplicableNovember 2026January 2027April 2027
October 25, 2026October 25, 2026Not ApplicableMarch 2027May 2027July 2027
February 25, 2027February 25, 2027Not ApplicableJuly 2027October 2027December 2027
June 25, 2027June 25, 2027Not ApplicableNovember 2027January 2028April 2028
October 25, 2027October 25, 2027Not ApplicableMarch 2028May 2028July 2028

Projects funded under PAR-25-104

NIH RePORTER lists 12 projects funded under PAR-25-104 in FY2022–FY2026, with $4.3M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.

Projects funded

12

Distinct projects, FY2022–FY2026

New awards

12

Type 1 (new project) award records

NIH funding

$4.3M

Award dollars under PAR-25-104, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-25-104
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202300$0
FY202400$0
FY202500$0
FY20261312$4.3M

Institutions with the most funding

  1. Northwestern University$962K · 1 project
  2. Dana-Farber Cancer Inst$341K · 1 project
  3. Baylor College of Medicine$321K · 1 project
  4. Mayo Clinic Arizona$319K · 1 project
  5. University of Minnesota$317K · 1 project
  6. Research Inst of Fox Chase Can Ctr$314K · 1 project
  7. Thomas Jefferson University$312K · 1 project
  8. New York University School of Medicine$310K · 1 project

Funding institutes

  • NCI$4.3M · 13

Activity codes funded

  • R3413 records

Most recent new awards

What its predecessor PAR-22-173 funded

PAR-25-104 reissues PAR-22-173. Its funding history is the best guide to who wins under this program: 17 projects and $13.1M in FY2022–FY2026.

Projects funded

17

Distinct projects, FY2022–FY2026

New awards

17

Type 1 (new project) award records

NIH funding

$13.1M

Award dollars under PAR-22-173, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-22-173
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202333$881K
FY2024129$3.6M
FY2025205$6.4M
FY2026100$2.3M

Institutions with the most funding

  1. University of Michigan at Ann Arbor$2.3M · 3 projects
  2. Duke University$1.7M · 2 projects
  3. H. Lee Moffitt Cancer Ctr & Res Inst$1.3M · 2 projects
  4. Oregon State University$908K · 1 project
  5. Northwestern University$869K · 1 project
  6. Virginia Commonwealth University$865K · 1 project
  7. Rutgers Biomedical and Health Sciences$862K · 1 project
  8. University of Houston$842K · 1 project

Funding institutes

  • NCI$13.1M · 45

Activity codes funded

  • R3445 records

Most recent new awards

FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.

Participating institutes

2 NIH institutes and offices take applications under PAR-25-104. Contact the program officer at the institute that fits your research before applying.

  • NCI · National Cancer Institute
  • none

Related notices

  1. Mar 31, 2025

    This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.

  2. Dec 17, 2024 · NOT-CA-25-023

    Notice of Correction to PAR-25-104, Cancer Prevention and Control Clinical Trials Planning Grant Program R34 Clinical Trials Optional). See Notice NOT-CA-25-023.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025.

  3. Aug 31, 2022 · NOT-OD-22-198

    Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.

  4. Aug 5, 2022 · NOT-OD-22-189

    Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.

Notices of Special Interest (NOSIs)

NIH has attached 6 NOSIs to PAR-25-104; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.

Award terms

Application types allowed
NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
Application budgets are limited to 225,000 per year and 450,000 in direct costs over the 3-year project period without a clinical trial.Applications that include a pilot/feasibility clinical trial are limited to 225,000 per year and 600,000 in direct costs over the 3-year project period.
Project period
The maximum project period is three years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Funds available and number of awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Related NOFOs

  • Reissue of PAR-22-173.
  • Companion NOFOs: PAR-25-103.

Other open NOFOs for R34

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO

NIH grant searchLook up awards by topic, PI, or institution.Find funded PIsInvestigators with recent NIH awards in your research area.Institute fit by topicWhich NIH institutes and institutions lead a research area.Funding trendsYear-by-year NIH award totals for any keyword.